JointHealth
français
Letters to Politicians

JointHealth™, through its parent organization Arthritis Consumer Experts (ACE), writes many letters to government. ACE writes to government on a broad range of issues-sometimes alone, and sometimes in partnership with other organizations.


Canada Canada
CETA-20120305.pdf Mar 5, 2012
Adalimumab-AS_NIHB_v.II.Final_20071210.pdf Dec 10, 2007

Alberta Alberta
ace-jh_letter_ab_arthritis_rehab_program_june11_2013.pdf Jun 10, 2013
ace-jh_letter_ab_horne_aug2012.pdf Aug 3, 2012
AB_psa_infliximab_20090112.pdf Jan 12, 2009
BRM-AS_AB_v.Final_20080102.pdf Jan 2, 2008
Adalimumab-AS_AB_v.II.Final_20071219.pdf Dec 19, 2007
Adalimumab-AS_AB_v.II.Final_20071212.pdf Dec 12, 2007
Adalimumab_AS_AB_v.Final_20070926.pdf Sep 26, 2007
Rituxan_AB_v.II.Final_20070815.pdf Aug 15, 2007
Abatacept_AB_v.Final_20070815.pdf Aug 15, 2007
Rituxan_AB_v.I.Final_20070320.pdf Mar 20, 2007
MOH_AB_v.Final_20061218.pdf Dec 18, 2006

British Columbia British Columbia
Leveling_the_Field_in_Canada-Biologic_Response_Modifier_Reimbursement-20120319.pdf Mar 19, 2012
MOH_Letter_de_Jong-20110525.pdf May 25, 2011
LetterToLiberalLeadershipCandidateFromACE.pdf Jan 31, 2011
Adalimumab-AS_BC_v.II.Final_20071202.pdf Dec 2, 2007
Adalimumab_AS_BC_v.Final_20070910.pdf Sep 10, 2007
Abatacept_BC_v.Final_20070815.pdf Aug 15, 2007
Rituxan_BC_v.II.Final_20070815.pdf Aug 15, 2007
Rituxan_BC_v.I.Final_20070315.pdf Mar 15, 2007
Abbott-Pharmacare_New_Drugs_v.Final_November-11-2006.pdf Nov 11, 2006
Premier_Campbell-September_6_2006_FINAL.pdf Sep 6, 2006

Manitoba Manitoba
manitoba_biologics_july6_2012_vf.pdf Jul 30, 2012
mb_letter_dec_9_2011.pdf Dec 9, 2011
BRM-AS_MB_v.Final_20080102.pdf Jan 2, 2008
Adalimumab-AS_MB_v.II.Final_20071219.pdf Dec 19, 2007
Adalimumab-AS_MB_v.II.Final_20071203.pdf Dec 3, 2007
Adalimumab_AS_MB_v.Final_20071002.pdf Oct 2, 2007
Abatacept_MB_v.Final_20070926.pdf Sep 26, 2007
Rituxan_MB_v.I.Final_20070320.pdf Mar 20, 2007
MOH_MB_v.Final_20061218.pdf Dec 18, 2006

New Brunswick New Brunswick
NB_psa_infliximab_20090302.pdf Mar 2, 2009
BRM-AS_NB_v.Final_20080102.pdf Jan 2, 2008
Adalimumab-AS_NB_v.II.Final_20071219.pdf Dec 19, 2007
Adalimumab-AS_NB_v.I.Final_20071210.pdf Dec 10, 2007
Adalimumab_AS_NB_v.Final_20070926.pdf Sep 26, 2007
Rituxan_NB_v.II.Final_20070815.pdf Aug 15, 2007
Abatacept_NB_v.Final_20070815.pdf Aug 15, 2007
Rituxan_NB_v.I.Final_20070320.pdf Mar 20, 2007
MOH_NB_v.Final_20061218.pdf Dec 18, 2006

Newfoundland and Labrador Newfoundland and Labrador
nl_letter_dec_9_2011.pdf Dec 9, 2011
NL_psa_infliximab_20090216.pdf Feb 16, 2009
BRM-AS_NL_v.Final_20080102.pdf Jan 2, 2008
Adalimumab-AS_NL_v.II.Final_20071219.pdf Dec 19, 2007
Adalimumab-AS_NL_v.II.Final_20071212.pdf Dec 12, 2007
Adalimumab_AS_NL_v.Final_20070926.pdf Sep 26, 2007
Rituxan_NL_v.II.Final_20070815.pdf Aug 15, 2007
Abatacept_NL_v.Final_20070815.pdf Aug 15, 2007
Rituxan_NL_v.I.Final_20070320.pdf Mar 20, 2007
MOH_NL_v.Final_20061218.pdf Dec 18, 2006

Northwest Territories Northwest Territories
nt_letter_dec_8_2011.pdf Dec 8, 2011
Adalimumab_AS_NT_v.Final_20070926.pdf Sep 26, 2007
Rituxan_NT_v.II.Final_20070815.pdf Aug 15, 2007
Abatacept_NT_v.Final_20070815.pdf Aug 15, 2007
Rituxan_NT_v.I.Final_20070320.pdf Mar 20, 2007
MOH_NT_v.Final_20061218.pdf Dec 18, 2006

Nova Scotia Nova Scotia
NS_psa_infliximab_20090302.pdf Mar 2, 2009
BRM-AS_NS_v.Final_20080102.pdf Jan 2, 2008
Adalimumab-AS_NS_v.II.Final_20071219.pdf Dec 19, 2007
Abatacept_NS_v.Final_20071127.pdf Nov 27, 2007
Rituxan_NS_v.II.Final_20070815.pdf Aug 15, 2007

Nunavut Nunavut
Adalimumab_AS_NU_v.Final_20070926.pdf Sep 26, 2007
Rituxan_NU_v.II.Final_20070815.pdf Aug 15, 2007
Abatacept_NU_v.Final_20070815.pdf Aug 15, 2007
Rituxan_NU_v.I.Final_20070320.pdf Mar 20, 2007
MOH_NU_v.Final_20061218.pdf Dec 18, 2006

Ontario Ontario
on_letter_dec_7_2011.pdf Dec 7, 2011
ACE-CAPA-LetterToOntarioMPP.pdf May 20, 2008
BRM-AS_ON_v.II.Final_20080102.pdf Jan 2, 2008
Adalimumab-AS_ON_v.II.Final_20071219.pdf Dec 19, 2007
Adalimumab-AS_ON_v.II.Final_20071212.pdf Dec 12, 2007
Adalimumab_AS_ON_v.Final_20070926.pdf Sep 26, 2007
Rituxan_ON_v.II.Final_20070815.pdf Aug 15, 2007
Abatacept_ON_v.Final_20070815.pdf Aug 15, 2007
Rituxan_ON_v.I.Final_20070320.pdf Mar 20, 2007
MOH_ON_v.Final_20061218.pdf Dec 18, 2006

Prince Edward Island Prince Edward Island
pe_letter_dec_9_2011.pdf Dec 9, 2011
BRM-AS_PE_v.Final_20080102.pdf Jan 2, 2008
Adalimumab-AS_PE_v.II.Final_20071219.pdf Dec 19, 2007
Adalimumab-AS_PE_v.II.Final_20071210.pdf Dec 10, 2007
Adalimumab_AS_PE_v.Final_20070926.pdf Sep 26, 2007
Rituxan_PE_v.II.Final_20070815.pdf Aug 15, 2007
Abatacept_PE_v.Final_20070815.pdf Aug 15, 2007
Rituxan_PE_v.I.Final_20070320.pdf Mar 20, 2007
MOH_PE_v.Final_20061218.pdf Dec 18, 2006

Québec Québec
Adalimumab-AS_QC_v.II.Final_20071219.pdf Dec 19, 2007
Adalimumab-AS_QC_v.II.Final_20071212.pdf Dec 12, 2007
Abatacept_QC_v.Final_20070815.pdf Aug 15, 2007
Rituxan_QC_v.I.Final_20070320.pdf Mar 20, 2007
MOH_QC_v.Final_20061218.pdf Dec 18, 2006

Saskatchewan Saskatchewan
sk_letter_dec_9_2011.pdf Dec 9, 2011
BRM-AS_SK_v.Final_20080102.pdf Jan 2, 2008
Adalimumab-AS_SK_v.II.Final_20071219.pdf Dec 19, 2007
Adalimumab_AS_SK_v.Final_20070919.pdf Sep 19, 2007
Rituxan_SK_v.II.Final_20070815.pdf Aug 15, 2007
Abatacept_SK_v.Final_20070815.pdf Aug 15, 2007
Rituxan_SK_v.I.Final_20070320.pdf Mar 20, 2007
MOH_SK_v.Final_20061215.pdf Dec 15, 2006

Yukon Yukon
yukon_letter_fall_2011.pdf Dec 9, 2011
Adalimumab-AS_YT_v.II.Final_20071210.pdf Dec 10, 2007
Adalimumab_AS_YT_v.Final_20070926.pdf Sep 26, 2007
Rituxan_YT_v.II.Final_20070815.pdf Aug 15, 2007
Abatacept_YT_v.Final_20070815.pdf Aug 15, 2007
Rituxan_YT_v.I.Final_20070320.pdf Mar 20, 2007
MOH_YT_v.Final_20061218.pdf Dec 18, 2006